BioSpace News Archive

The amyloid plaque targeting therapy met primary endpoint and all secondary endpoints, which Lilly will use in its submission to the FDA this quarter.

The company’s pipeline changes come as it weathered a nearly 30% decline in first-quarter revenues due to a slowdown in its COVID-19 business.

Many employers aren’t offering the high salaries employees had grown accustomed to in recent years, leaving workers to decide whether they should accept a pay cut.

Despite the Phase III failure, Travere and partner CSL Vifor will explore potential regulatory paths for sparsentan as a treatment for focal segmental glomerulosclerosis.

The regulatory decision marks a turning point in the RSV race in what’s expected to be a competitive space.

NeoGenomics, Inc.today announced the company will be participating in the upcoming BofA Securities 2023 Healthcare Conference in Las Vegas, Nevada.

Marinus Pharmaceuticals, Inc. today announced that management will present and participate during the following conferences in May.

Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS ® (Voclosporin) For Adults with Active Lupus Nephritis.

Mersana Therapeutics, Inc. today announced that members of management will present at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023 at 12:20 p.m. Eastern Time.

BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its first quarter 2023 financial results as well as operational highlights before the open of the U.S. financial markets on Wednesday, May 17, 2023.